Effects of five Chinese patent medicines on focal cerebral ischemia of rats and comparison on their mechanisms
- Author:
Qing ZHU
1
Author Information
1. College of Pharmacy
- Publication Type:Journal Article
- Keywords:
Buchang naoxintong capsula;
Focal cerebral ischemia;
Fufang xueshuantong capsula;
Tongsaimai tablet;
Tongxinluo capsula;
Xuesaitong capsula
- From:
Chinese Traditional and Herbal Drugs
2011;42(6):1149-1153
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the difference of therapeutical effect with Tongsaimai Tablet, Tongxinluo Capsula, Buchang Naoxintong Capsula, Fufang Xueshuantong Capsula and Xuesaitong Capsula on focal cerebral ischemia of rats. Methods: The focal cerebral ischemia of rats was made by electric coagulation with middle cerebral artery (MCA). The score of ethology, the area of cerbral infarction, AngI, AngII in plasma, C-reactive protein (CRP) in serum, and NF-κB expression were examined to observe the effect of these five Chinese patent medicines by ig administration of Tongsaimai Tablet (0.239 g/kg), Tongxinluo Capsula (0.281 g/kg), Buchang Naoxintong Capsula (0.432 g/kg), Fufang Xueshuantong Capsula (0.405 g/kg), and Xuesaitong Capsula (0.027 g/kg) twice a day for 3 d. Results: Every group of the five Chinese patent medicines could significantly reduce the area of cerebral infarction and the expression of NF-κB. The score of ethology was more lower with Xuesaitong Capsula. The content of IL-6 in plasma was cut down greatly by Tongxinluo Capsula, Buchang Naoxintong Capsula, Xuesaitong Capsula, and Tongsaimai Tablet. The content of CRP in serum was reduced with Xuesaitong Capsula and Buchang Naoxintong Capsula. The content of AngII in plasma was degraded by Tongsaimai Tablet (P<0.05, 0.01). Conclusion: Every Chinese patent medicine can inhibit the release of inflammatory factor at varying degrees. These five Chinese patent medicines can degrade the expression of NF-κB so as to ameliorate cerebral ischemia, and Tongsaimai Tablet can cut down the content of AngII in plasma to lessen the symptom of cerebral ischemia.
